Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 19, 2023 - Issue
Submit an article Journal homepage
249
Views
0
CrossRef citations to date
0
Altmetric
REVIEW

Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability

Maximiliano Diaz-Menindez1 Division of Pulmonary, Allergy, and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, FL, USAView further author information
,
Dan Morgenstern-Kaplan2 Department of Internal Medicine, University of Miami/Jackson Health System, Miami, FL, USAView further author information
,
Lyda Cuervo-Pardo3 Division of Rheumatology, Allergy and Clinical Immunology, Department of Medicine, University of Florida, Gainesville, FL, USAView further author information
,
Santiago Alvarez-Arango4 Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;5 Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USAView further author information
&
Alexei Gonzalez-Estrada6 Division of Allergy, Asthma and Clinical Immunology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5754-6130View further author information
ORCID Icon
Pages 313-317 | Received 04 Oct 2022, Accepted 27 Feb 2023, Published online: 30 Mar 2023

References

  • Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77:1961–1990. doi:10.1111/all.15214
  • Valerieva A, Longhurst HJ. Treatment of hereditary angioedema-single or multiple pathways to the rescue. Front Allergy. 2022;3:952233. doi:10.3389/falgy.2022.952233
  • Busse PJ, Christiansen SC. Hereditary Angioedema. N Eng J Med. 2020;382:1136–1148. doi:10.1056/NEJMra1808012
  • Arruda LK, Ferriani MPL. Treatment of hereditary angioedema: when the goal is having a normal life. J Allergy Clin Immunol. 2021;148:80–82. doi:10.1016/j.jaci.2021.05.023
  • Hwang JR, Hwang G, Johri A, Craig T. Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema. Immunotherapy. 2019;11:1439–1444. doi:10.2217/imt-2019-0128
  • BioCryst Pharmaceuticals I ORLADEYO™ (berotralstat) capsules, for oral use. U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf. Accessed February 27, 2023. 2020.
  • Aygören-Pürsün E, Bygum A, Grivcheva-Panovska V, et al. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. N Engl J Med. 2018;379:352–362. doi:10.1056/NEJMoa1716995
  • Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67:1289–1298. doi:10.1111/all.12007
  • Longhurst H, Moldovan D, Bygum A, et al. Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: results of the ZENITH-1 Trial. J Allergy Clin Immunol. 2019;143:AB36. doi:10.1016/j.jaci.2018.12.112
  • Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled Phase 3 trial. J Allergy Clin Immunol. 2021;148:164–172.e169. doi:10.1016/j.jaci.2020.10.015
  • Wedner HJ, Aygören-Pürsün E, Bernstein J, et al. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: results of APeX-2 Through 48 Weeks (Part 2). J Allergy Clin Immunol Pract. 2021;9:2305–2314.e2304. doi:10.1016/j.jaip.2021.03.057
  • Ohsawa I, Honda D, Suzuki Y, et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy. 2021;76:1789–1799. doi:10.1111/all.14670
  • Farkas H, Stobiecki M, Peter J, et al. Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy. 2021;11:e12035. doi:10.1002/clt2.12035
  • Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:193–204. doi:10.1016/j.anai.2010.01.007

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.